Date: 2012-05-21
Type of information: Development agreement
Compound: ML7
Company: Provence Technologies (France) Neuroptis Biotech (France)
Therapeutic area: Ophtalmological diseases
Type agreement: development
Action mechanism:
Disease: dry eye syndrome
Details: Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, have announced the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012. Provence Technologies and Neuroptis Biotech have already collaborated successfully in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches, and devising associated analytical methods. The two companies have embarked on the process optimization phase to facilitate the transfer of the compound and the start of production on an industrial scale, scheduled for September this year.
Financial terms:
Latest news:
